Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population: A Multinational Case Series

Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population. Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination. Twenty individuals were included. The most common event wa...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2024-09, Vol.ahead-of-print (ahead-of-print), p.1-6
Main Authors: Testi, Ilaria, Brandão-de-Resende, Camilo, De-La-Torre, Alejandra, Concha-Del-Rio, Luz Elena, Cheja-Kalb, Rashel, Mahendradas, Padmamalini, Habot-Wilner, Zohar, Yalçındağ, Nilüfer, Markelj, Špela, Iriqat, Salam, Portero, Alejandro, Petrushkin, Harry, Pavesio, Carlos, Solebo, Ameenat Lola
Format: Article
Language:English
Subjects:
Adolescent
Child
Child, Preschool
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Female
Glucocorticoids - therapeutic use
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Male
ocular inflammation
paediatric
Retrospective Studies
SARS-CoV-2
uveitis
Uveitis - diagnosis
Uveitis - etiology
vaccination
Vaccination - adverse effects
Visual Acuity - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population. Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination. Twenty individuals were included. The most common event was anterior uveitis (n = 8, 40.0%), followed by intermediate uveitis (7 patients, 35%), panuveitis (4 patients, 20%), and posterior uveitis (1 patient, 5%). The event was noticed in the first week after vaccination in 11 patients (55.0%). Twelve patients (60.0%) had a previous history of intraocular inflammatory event. Patients were managed with topical corticosteroids (n = 19, 95.0%), oral corticosteroids (n = 10, 50.0%), or increased dose of immunosuppressive treatment (n = 6, 30.0%). Thirteen patients (65.0%) had a complete resolution of the ocular event without complications. All patients had a final visual acuity unaffected or less than three lines of loss. Ocular inflammatory events may happen in the paediatric population following COVID-19 vaccination. Most events were successfully treated, and all showed a good visual outcome.
ISSN:0927-3948
1744-5078
1744-5078
DOI:10.1080/09273948.2023.2220782